The susceptibilities of 44 clinical strains and a reference strain (ATCC 23834) of EikeneUa corrodens were determined by agar dilution. All isolates were very susceptible (MICs, <2 ,ug/ml) to amifloxacin, ciprofloxacin, difloxacin, enoxacin, norfloxacin, ofloxacin, and Win 35439. Eikenella corrodens is a fastidious gram-negative rod that has been implicated as a pathogen in a variety of infections including abscesses, dental infections, sinusitis, osteomyelitis, lower respiratory tract infections, and endocarditis (1-4, 6, 8, 10, 11). Multiple prior studies have reported that all clinical strains of E. corrodens were susceptible to penicillin G (1, 5, 9). Recently, Trallero et al. (12) reported the isolation of beta-lactamase-producing E. corrodens from intraabdominal abscesses in a 10-year-old boy. Consequently, they recommended that clinical laboratories should now "initiate susceptibility studies of these organisms." E. corrodens is resistant to clindamycin, penicillinase-resistant penicillins, and currently available oral cephalosporins (1, 5). There is, therefore, a need for an oral antimicrobial agent that is consistently active against E. corrodens.
The susceptibilities of 44 clinical strains and a reference strain (ATCC 23834) of EikeneUa corrodens were determined by agar dilution. All isolates were very susceptible (MICs, <2 ,ug/ml) to amifloxacin, ciprofloxacin, difloxacin, enoxacin, norfloxacin, ofloxacin, and Win 35439.
Eikenella corrodens is a fastidious gram-negative rod that has been implicated as a pathogen in a variety of infections including abscesses, dental infections, sinusitis, osteomyelitis, lower respiratory tract infections, and endocarditis (1-4, 6, 8, 10, 11) . Multiple prior studies have reported that all clinical strains of E. corrodens were susceptible to penicillin G (1, 5, 9) . Recently, Trallero et al. (12) reported the isolation of beta-lactamase-producing E. corrodens from intraabdominal abscesses in a 10-year-old boy. Consequently, they recommended that clinical laboratories should now "initiate susceptibility studies of these organisms." E. corrodens is resistant to clindamycin, penicillinase-resistant penicillins, and currently available oral cephalosporins (1, 5) . There is, therefore, a need for an oral antimicrobial agent that is consistently active against E. corrodens.
The new quinolones are a group of oral agents that have a broad spectrum of activity (13). They are currently undergoing clinical trials in a variety of situations in which E. corrodens is a potential pathogen (7) . We therefore studied the in vitro activity of penicillin, vancomycin, and new and old quinolones against members of our stock strain collection, as well as against 20 recently isolated strains of E. corrodens.
All 44 strains tested were clinical isolates and were identified by standard criteria (1) . The sources of the isolates were as follows: 12 from wounds, 11 Although the susceptibility of common pathogens to the newer quinolones has been well studied (13), the susceptibility of less common and fastidious pathogens is frequently overlooked. The recent development of beta-lactamase activity by some strains of E. corrodens (12) coupled with the poor activity of penicillinase-resistant penicillins, currently available oral cephalosporins, and clindamycin (1, 5, 9) poses a potential therapeutic dilemma for clinicians choosing an oral antimicrobial regimen when E. corrodens may be present. Clinical evidence of therapeutic failure has been correlated with the in vitro findings that the E. corrodens strain isolated was resistant to the antibiotic used (1, 4, 11) . The newer quinolones are being studied for efficacy in a wide variety of infections, including those in which E. corrodens may be present (7) . Because E. corrodens is a fastidious, slow-growing organism, it may be overgrown in mixed culture, or it may be missed on routine culture. Our data suggest that all the newer quinolones tested would be active against E. corrodens and could be used empirically in situations where E. corrodens is a potential pathogen.
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